CBDL (CBD Life Sciences) Equity-to-Asset: 0.34 (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CBD Life Sciences Equity-to-Asset?

CBD Life Sciences CBDL Equity-to-Asset is 0.34 as of Sep. 2015.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CBD Life Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2015 was $0.21 Mil. CBD Life Sciences's Total Assets for the quarter that ended in Sep. 2015 was $0.62 Mil.

The historical rank and industry rank for CBD Life Sciences's Equity-to-Asset or its related term are showing as below:

CBDL's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6
* Ranked among companies with meaningful Equity-to-Asset only.

CBD Life Sciences  (OTCPK:CBDL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

CBD Life Sciences Equity-to-Asset Related Terms

CBD Life Sciences Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for CBD Life Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CBD Life Sciences Equity-to-Asset Chart

CBD Life Sciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14
Equity-to-Asset
1.07 0.94 0.12 -0.02

CBD Life Sciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.02 0.42 0.37 0.34

CBDL vs QPAG, ADGO, MCCX: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CBD Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CBD Life Sciences Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CBD Life Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CBD Life Sciences's Equity-to-Asset falls into.


CBD Life Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CBD Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Equity to Asset (A: Dec. 2014 )=Total Stockholders Equity/Total Assets
=-0.013/0.632
=-0.02

CBD Life Sciences's Equity to Asset Ratio for the quarter that ended in Sep. 2015 is calculated as

Equity to Asset (Q: Sep. 2015 )=Total Stockholders Equity/Total Assets
=0.209/0.621
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.34 mean?
CBD Life Sciences (CBDL) has a Equity-to-Asset of 0.34 as of Sep. 2015. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CBD Life Sciences and its competitors.
Is CBD Life Sciences' Equity-to-Asset too high?
CBD Life Sciences' current Equity-to-Asset is 0.34. The Drug Manufacturers industry median Equity-to-Asset is 0.60. CBD Life Sciences' value of 0.34 is 43.3% below this industry median.
How does CBD Life Sciences' Equity-to-Asset compare to QPAG and ADGO?
CBD Life Sciences' Equity-to-Asset of 0.34 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. CBD Life Sciences' value of 0.34 is 43.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CBD Life Sciences's current Equity-to-Asset of 0.34 is 43.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CBD Life Sciences and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CBD Life Sciences's current Equity-to-Asset is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CBD Life Sciences stock overvalued right now?
CBD Life Sciences (CBDL) has a current Equity-to-Asset of 0.34. The current Equity-to-Asset is 0.34 and 43.3% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CBD Life Sciences (CBDL), the current Equity-to-Asset is 0.34 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CBD Life Sciences Business Description

Address 10953 N. Frank Llyod Wright Boulevard, Unit 108, Scottsdale, AZ, USA, 85259
CBD Life Sciences Inc is developing and marketing a line of cannabidiol-based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products.